Summary Methylation has been shown to play an important role in the down-regulation of oestrogen receptors (ER) in breast cancer cells. One critical question that remains unclear is whether methylation can account for the loss of ER expression in cells derived from an ERpositive cell line. This laboratory has established an in vitro cell system using long-term growth of human ER-positive breast cancer cell line T47D in oestrogen-free medium. A clonal cell line, T47D:C4:2 (C4:2), has been characterized. Unlike T47D:A18 (A18), which is a T47D line maintained in oestrogen medium, C4:2 has lost the expression of ER and hormone responsiveness. DNA fingerprinting and restriction fragment length polymorphism (RFLP) analysis results confirmed that C4:2 was of the same lineage as A18. These cell lines provide an invaluable system to study the mechanism of ER expression and regulatory pathways leading to hormone-independent growth. The results here clearly demonstrate that the ER CpG island in C4:2 cells remains unmethylated. The loss of ER in the cell line must be due to mechanisms other than methylation. We also evaluated the ER CpG island in the MDA-MB-231 :10A (10A) cell line, which is a clone from the MDA-MB-231 line obtained from ATCC and the DNA from the MDA-MB-231 cell line used in the original report. Unlike the cell line from the report, which showed a full methylation pattern in the island, the 1 OA line only showed a partial methylation pattern in the CpG island. Possible mechanisms pertaining to the heterogeneous methylation pattern of the ER CpG island in the breast cancer cells are discussed.
The presence of functional oestrogen receptors (ER) in breast cancer predicts the clinical response of a patient to endocrine therapy (Jordan, 1994) . ER-positive patients respond well to antioestrogens such as tamoxifen, which produces a favourable response in up to 60% of the patients (Lemer and Jordan, 1996) . Unfortunately, hormone dependency is ultimately lost in advanced breast cancer after an initial response to the therapy. The loss of ER expression in recurrent breast cancer has been closely associated with poor response to endocrine therapy (Kuukasjarvi et al, 1996) . ER expression is therefore critical for the control of hormone-dependent breast cancer. An understanding of ER regulation to maintain the control of breast cancer growth with hormone antagonists would be an invaluable goal and provide a useful therapeutic target. However, the molecular mechanisms of ER regulation and disease progression remain largely unknown.
Ideally, precise information about the loss of ER should be obtained from well-characterized laboratory models. However, until recently, there were no human models available to address molecular mechanisms of ER regulation. Recently, we have described two models of ER regulation in breast cancer cells . ER in MCF-7 cells is down-regulated by oestrogen but in T47D cells oestrogen is capable of up-regulating ER. With this knowledge, we focused our attention on the T47D cell line to develop a model of ER loss by long-term oestrogen deprivation. Initially, our stocks of T47D cells were ER positive and oestrogen would induce growth and progesterone receptor synthesis. After years of long-term oestrogen deprivation, we successfully cloned our ER-negative cell lines that have irreversibly lost ER . We confirmed that the cells are from the same patient using restriction fragment length polymorphism (RFLP) using single locus probes. Thus, the cells provide a unique opportunity to study the molecular mechanism for the loss of ER.
Recent studies have demonstrated a close correlation between hypermethylated 5' CpG islands and inactivation of the corresponding downstream genes including p16 , E-cadherin (Graff et al, 1995) , von Hippel-Lindau (Herman et al, 1994) and ER Issa et al, 1994 Issa et al, , 1996a Issa et al, , 1996b Ferguson et al, 1995) in human cancers. In breast cancer, methylation of the ER CpG island was detected in some ER-negative breast cancer cell lines. Most encouraging was the observation that treatment of cells with the methylation inhibitor deoxyazacytidine results in the re-expression of ER in the ER-negative MDA-MB-231 breast cancer cells (Ferguson et al, 1995) . In addition, aberrant methylation of this ER promoter region was also found in nine out of nine leukaemia cell lines examined, 86% of the human haematopoietic tumours (Issa et al, 1996b ) and 100% of human colorectal tumours . For lung cancer, methylation of this region appears to depend on exposure to carcinogens (Issa et al, 1996a) . There was no significant difference in the methylation pattern between smokers and non-smokers. However, spontaneous and plutonium-induced lung tumours had a 82% incidence of the aberrant methylation in this ER CpG island compared with about 17% lung tumours with hypermethylation in response to tobacco-derived carcinogen exposure in rodent models. Nevertheless, studies using existing cell lines and specimens from Jordan, 1992) . T47D:C4:2 (C4:2) was cloned from T47D in oestrogen-free media (Murphy et al, 1990 (Ferguson et al, 1995) . The media were shown changed once every 2 days with freshly prepared compounds.
non-oestrogen target tissues leave open the critical question of whether methylation is the cause of gene silencing or an epigenetic mean used by organisms to stabilize the inactive state of the unexpressed genes. Even in the case of the breast cancer cell lines, there is no evidence that the cells were ever ER positive.
Using the unique cell model , we tested the hypothesis that methylation of the CpG island is the fundamental mechanism responsible for the loss of ER expression in breast cancer cells. The results showed that ER CpG island is not methylated in either C4:2 or A18 cell lines. As these two cell lines were derived from the same progenitor, this study not only suggests that methylation of the region is not a prerequisite for the loss of ER expression, but also challenges the theory of methylation as the primary cause of ER down-regulation in breast cancer cells. 
MATERIALS AND METHODS

RESULTS
Methylation of the CpG island in ER promoter was determined using methylation-sensitive restriction endonucleases including SaclI and HhaI, as described previously (Ferguson et al, 1995) . BsmI, which is methylation insensitive, was used to generate the 1.3-kb fragment of the DNA that includes the CpG island. When the island is not methylated, a complete digestion of the BsmI fragment should produce three bands corresponding to approximately 0.83, 0.26 and 0.2 kb for SacII and four bands of 0.38, 0.35, 0.28 and 0.22 kb for HhaI (Figure 1) . The results are shown in Figure 2 . As expected, restriction digests of ER-positive MCF-7 DNA resulted in complete digestion, indicating that the CpG island was not methylated (lanes 1-3) . The results from the ER-negative MDA-MB-231:10A cells showed the island was only methylated in the two most 5' HhaI sites and minimally methylated in the most 3' HhaI site (lanes 4-6). Unlike the lOA cell line, the other MDA-MB-231 cell line showed complete methylation in this region (lanes 7-9), as previously reported (Ferguson et al, 1995 (Reis and Goldstein 1982) .
To evaluate the role of methylation in an ER-negative cell line derived from ER-positive T47D cell line, we compared the CpG islands in C4:2 and A18 cell lines. The results showed that, as in A18 (lanes 10-12), C4:2 had a completely unmethylated CpG island in the ER promoter (lanes 13-15). This observation strongly suggests that hypermethylation does not play a role in the loss of ER expression during the conversion from hormone sensitive to hormone independent in this cell line. There was a possibility that critical residues in the island were methylated and undetected by the restriction enzymes used. This possibility was tested by treating the cells with deoxyC and azaC. The results showed that deoxyC treatment on 1OA cells (lanes 16-18) and C4:2 cells (lanes 19-21) had little effect on the partially methylated and unmethylated CpG island. Treatment of the cells with azaC showed the identical results (data not shown). A recent study on human 0-6-methylguanine DNA methyltranserase (MGMT) suggested that methylation of the CpG island containing all the relevant transcription factor binding sites was unnecessary for silencing of MGMT expression (Pieper et al, 1996) .
To correlate the methylation pattern with ER expression, total RNA and proteins isolated from the cell lines were analysed using Northern blot and Western blot techniques. These results show a clear correlation between hormone responsiveness and ER expression as expected. In contrast, the correlation of methylation and ER expression appeared to be complicated. ER down-regulation was associated with full methylation of the ER CpG island in one MDA-MB-231 cell line and a partial methylation pattern in 1OA or with an unmethylated CpG island in C4:2 cells. DISCUSSION This study demonstrates clearly that the ER CpG island in C4:2 remains unmethylated after the loss of ER expression in T47D cells, and the results demonstrate that the loss of ER expression in breast cancer cells does not require methylation of the CpG island. Whether the methylation can eventually occur in C4:2 remains to be seen. These results are consistent with a recent report (Safarians et al, 1996) from somatic cell hybridization studies that also demonstrated that the loss of ER in the C8161 x MCF-7 hybrids was not due to methylation of the CpG island. The studies suggested that the presence of dominant trans-acting factors played a key role in the regulation of ER expression in the hybrids.
The association of CpG island methylation and suppression of gene expression has been well documented (Cross and Bird, 1995; Martienssen and Richards, 1995) . Housekeeping genes and a large number of the tissue-specific genes contain CpG islands at the 5' end of the genes. Under normal conditions, the CpG islands are unmethylated. The precise molecular mechanism of methylation is still under vigorous investigation, but one possible mechanism of the maintenance of the methylation-free island is the binding of transcription factors such as Spl in the promoter/enhancer region (Razin and Cedar, 1994; Cross and Bird, 1995) . In agreement with this model, it is likely that the loss of factors binding to a CpG island may render the sites susceptible to DNA methyltransferase and result in aberrant hypermethylation of this region for some genes, including ER in cancers. Strong evidence in support of this model came from the observations that the p16 CpG island is hypermethylated whereas ER CpG island is unmethylated in the same T47D breast cancer cell line (Ferguson et al, 1995; Herman et al, 1995) . The loss of promoter/enhancer-specific factors may better explain the promoter-specific methylation than does the level of the DNA methyltransferase because the events occur in the same cell. This model also leaves open the possibility that the loss of the promoter/enhancer-binding factors, including transcriptionally active factors, may come first before methylation occurs. The results from C4:2 may be explained by this mechanism.
The scenario that methylation of the ER CpG island requires stepwise inactivation of the factors critical for the protection of the area may explain the heterogeneous methylation pattems observed in breast cancer cells. When subsequent loss of the factors occurs, hypermethylation may provide an efficient way to preserve the inactive state of the ER CpG island in the cells. Otherwise, the ER CpG island will remain unmethylated and the cells will continue to show the loss of ER expression. From this perspective, the methylation results observed in C4:2 cells are consistent with the previous findings that hypermethylation of ER CpG island occurs in some but not all of the breast cancer cells (Ferguson et al, 1995) . One essential prerequisite for this model is that de novo methylation must be able to take place. Studies using neoplastic colon tissues suggested that methylation of the p16 CpG island occurred during progression from early lesion to the carcinomatous lesion . The ER and E-cadherin CpG islands were shown to be unmethylated in MCF-7 breast cancer cells and subsequently became hypermethylated in a drug-resistant subline MCF-7/ADR (Graff et al, 1995; Ottaviano et al, 1994) . These studies suggested that de novo methylation can occur as the result of tumour progression.
Other mechanisms, such as gene rearrangement, can also result in the loss of gene expression (Carter et al, 1990; Kamb et al, 1994; Nobori et al, 1994) . The results in Figure 2 and restriction analysis show no major structural alterations of the ER gene and the promoter region in C4:2 cells. The loss of transcription activators may also result in the loss of gene expression. A putative ER regulatory factor, ERF-1, was reported to stimulate ER expression in T47D cells (deConinck et al, 1995) . We are in the process of evaluating the role of ERF-1 as the mechanism for the loss of ER in the cell line. The possible. role of dominant trans-acting factors (Safarians et al, 1996) offers another alternative mechanism for the control of ER expression.
In conclusion, our findings showed that methylation of the CpG island is not required for the loss of ER expression in ER-negative breast cancer cells derived from ER-positive cells. The results do not rule out the possibility that methylation can be an alternative mechanism in some cells or a subsequent event after the loss of expression of the gene. The C4:2 and A18 cells are an excellent new model for the study of the regulation of ER expression and regulatory pathways leading to hormone independent growth of breast cancer cells.
